1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Jiangsu Kanion Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

Jiangsu Kanion Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 23 pages

Jiangsu Kanion Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Jiangsu Kanion Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013” provides data on the Jiangsu Kanion Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Jiangsu Kanion Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Jiangsu Kanion Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Jiangsu Kanion Pharmaceutical Co., Ltd. - Brief Jiangsu Kanion Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Jiangsu Kanion Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Jiangsu Kanion Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Jiangsu Kanion Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Jiangsu Kanion Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Jiangsu Kanion Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Jiangsu Kanion Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Jiangsu Kanion Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Jiangsu Kanion Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

Jiangsu Kanion Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Jiangsu Kanion Pharmaceutical Co., Ltd. Snapshot 4
Jiangsu Kanion Pharmaceutical Co., Ltd. Overview 4
Key Information 4
Key Facts 4
Jiangsu Kanion Pharmaceutical Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products Glance 9
Jiangsu Kanion Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Jiangsu Kanion Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 10
Unknown Products/Combination Treatment Modalities 10
Jiangsu Kanion Pharmaceutical Co., Ltd. - Drug Profiles 11
KYG-0395 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
NT-004 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
NT-113 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
NT-125 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Analysis 15
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Therapeutic Class 15
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Target 16
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 17
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 18
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 19
Jiangsu Kanion Pharmaceutical Co., Ltd. - Recent Pipeline Updates 20
Jiangsu Kanion Pharmaceutical Co., Ltd. - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23



List of Tables

Jiangsu Kanion Pharmaceutical Co., Ltd., Key Information 4
Jiangsu Kanion Pharmaceutical Co., Ltd., Key Facts 4
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Indication, 2013 6
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 7
Jiangsu Kanion Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
Jiangsu Kanion Pharmaceutical Co., Ltd. - Phase II, 2013 9
Jiangsu Kanion Pharmaceutical Co., Ltd. - Unknown, 2013 10
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Therapeutic Class, 2013 15
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Target, 2013 16
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2013 17
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2013 18
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2013 19
Jiangsu Kanion Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2013 20



List of Figures

Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2013 6
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 7
Jiangsu Kanion Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Top 10 Therapeutic Class, 2013 15
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2013 16
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2013 17
Jiangsu Kanion Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2013 19



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.